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Abstract
Introduction: Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical
features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term 
adverse outcomes.
Aims: To review the evidence on rimonabant, a novel CB1 receptor antagonist, for the treatment of obese and overweight patients.
Evidence review: There is clear evidence that rimonabant 20 mg/day in conjunction with a hypocaloric diet causes a mean weight loss
of 4.6 kg in obese and overweight patients after 1 year’s treatment, with approximately 50% of patients achieving a weight loss of ≥5%.
One study demonstrated that weight loss is maintained for up to 2 years. The drug also improves lipid and glycemic cardiovascular risk
factors, including high-density lipoprotein cholesterol and insulin resistance, and reduces waist circumference, thus reducing the
prevalence of metabolic syndrome. Treatment of obese and overweight diabetic patients with rimonabant decreases glycosylated
hemoglobin (HbA1c), including patients previously untreated for diabetes. The effect of rimonabant appears to be partly independent of
weight loss.
Rimonabant 20 mg/day is generally well tolerated, with mild to moderate transient adverse effects including nausea, diarrhea, dizziness,
and anxiety. Approximately 14% of patients receiving rimonabant 20 mg/day discontinued due to adverse effects, primarily depressed
mood, although overall rates of depression did not differ significantly compared with placebo.
Place in therapy: The evidence supports the use of rimonabant 20 mg/day along with dietary modification to reduce cardiovascular risk
factors in obese and overweight patients, including those with diabetes. The drug is contraindicated in patients receiving
antidepressants. Long-term data on cardiovascular outcomes, morbidity, and mortality are eagerly awaited.
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Core evidence place in therapy summary for rimonabant 20 mg/day in obese and overweight
patients in combination with hypocaloric diet 
Outcome measure Evidence Implications
Patient-oriented evidence
Quality of life Moderate Rimonabant may improve quality of life, particularly physical functioning
Improved nutritional status Moderate Some patients may find it easier to follow diet during rimonabant treatment
Reduced morbidity and mortality No evidence Should be benefit but requires confirmation
Tolerability Clear Depressed mood may cause discontinuation of treatment in some patients,
and rimonabant should not be used in those with depression. Rimonabant
can cause mild and transient adverse effects, particularly nausea, diarrhea,
dizziness, and anxiety
Disease-oriented evidence
Weight reduction in medium term (<1 year) Clear Weight loss ≥5% can be achieved in approximately 50% of patients 
Weight reduction in long term (>1 year) Moderate Weight loss can be maintained for up to 2 years
Waist circumference Clear Significant decrease in waist circumference can be achieved with
rimonabant within 9 months
Lipid profiles Clear Rimonabant is effective in raising HDL-C, lowering triglycerides, and
improving total:HDL and LDL:HDL ratios for up to 2 years
Insulin resistance and glycemic variables Substantial Rimonabant can reduce HbA1c, insulin resistance, and fasting glucose and
insulin for up to 1 year
continued overleaf...Scope, aims, and objectives
The increasing worldwide prevalence of obesity and overweight,
and the related constellation of risk factors known as the
metabolic syndrome (including dyslipidemia, insulin resistance,
hypertension, and vascular endothelial dysfunction) are thought
to underlie a growing pandemic of cardiovascular disease,
diabetes, and certain types of cancer. It is estimated that 90% of
type 2 diabetes cases are directly caused by obesity (James &
Rigby 2004), and between 112 000 and 280 000 deaths per
annum in the USA are attributable to obesity-related disease
(Allison et al. 1999; Flegal et al. 2005). In addition to reducing
long-term life expectancy, obesity is associated with substantial
morbidity, disability, and impairment of quality of life.
Comorbidities directly linked with obesity include respiratory
difficulties, sleep apnea, infertility, skin disorders, and
psychologic dysfunction arising from poor self-esteem
(Khaodhiar et al. 1999; Pender & Pories 2005). Interventions to
address obesity include appropriate diet, educational initiatives,
and exercise. However, drug therapy may be indicated in
patients for whom these measures alone are ineffective. 
The multifactorial etiology of obesity has sparked numerous lines
of research exploring novel therapeutic targets. One such target
is the endocannabinoid system, a neuroendocrine pathway
involved in the regulation of reward behavior, appetite, and
energy homeostasis. Endocannabinoids have physiologic
functions in the central nervous system and peripheral organs
such as adipose tissue and gut, involving complex modulation
and feedback mechanisms (Di Marzo et al. 2001; Pagotto et al.
2005). Evidence from animal models suggests that overactivity of
the endocannabinoid system may be associated with obesity,
and that blockade of endocannabinoid CB1 receptors is
associated with reductions in food intake and body weight
(Kirkham & Williams 2004). Rimonabant (SR-141716A;
Acomplia®, Sanofi-Aventis) is a novel CB1 antagonist. This article
reviews the evidence of the effectiveness of rimonabant in 
the treatment of obese or overweight patients, including those
with additional cardiovascular risk factors associated with 
metabolic syndrome.
Methods
The English language medical literature was reviewed for
appropriate articles relating to rimonabant for the treatment of
obesity and/or the metabolic syndrome. The search terms used
were “rimonabant,” “rimonabant AND obesity,” “rimonabant AND
metabolic syndrome,” and “rimonabant AND diabetes.” The
following databases were searched during July 2005 and then
updated in December 2006 as indicated below:
• PubMed, http://www.ncbi.nlm.nih.gov/entrez/query.fcgi
• EMBASE, http://www.datastarweb.com
• BIOSIS, http://www.datastarweb.com
• Database of Abstracts of Reviews of Effects (DARE), National
Health Service (NHS) Economic Evaluation Database
(NHSEED) Health Technology Assessment (HTA),
http://www.york.ac.uk/inst/crd/darehp.htm
• Cochrane Library, http://www3.interscience.wiley.com/cgi-
bin/mrwhome/106568753/HOME
• Clinical Evidence, http://www.clinicalevidence.com
No date restrictions were placed on the above literature
searches. Additional searches to identify relevant data presented
since 2001 at the annual scientific meetings of the American
College of Cardiology, the American Diabetes Association, 
the American Heart Association, and the European Society 
of Cardiology were conducted using the search terms 
outlined above.
The initial search identified 38 full papers and 121 abstracts
(defined for the purpose of this article as nonpeer-reviewed
literature including abstracts presented at scientific meetings,
editorials/opinion articles, and meeting highlights reports). Of the
38 full papers, two publications contained clinical evidence on
rimonabant, one randomized controlled trial (RCT) (Van Gaal et
al. 2005), and one observational case report (van Oosten et al.
2004). Of the abstracts, 13 publications identified by the initial
search contained clinical data on rimonabant. Following removal
of duplicates, six abstracts were included from this initial
literature search (Table 1).
The PubMed English language literature search was updated on
December 12, 2006 with the following limits: publication date
August 1, 2005 to December 12, 2006; humans; clinical trial;
randomized controlled trial; meta analysis. The updated search
revealed four new records, one of which was excluded because
it was out of scope. The remaining three records were
categorized as level 2 evidence. A level 1 systematic review from
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...table continued
Outcome measure Evidence Implications
Metabolic syndrome Substantial Rimonabant can reduce the prevalence of metabolic syndrome
Adiponectin levels Substantial Rimonabant can increase plasma adiponectin and reduce leptin levels
implying direct metabolic effect
Blood pressure Clear Rimonabant has a neutral effect on blood pressure after 1 year
HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein.October 18, 2006 was identified in the Cochrane Library.
Finally, the abstracts of the International Diabetes Federation
2006 World Diabetes Congress were also searched, yielding a
report of a level 2 study.
Disease overview
Epidemiology
The obesity pandemic is one of the most challenging public
health issues facing the developed world. The World Health
Organization estimates that worldwide there are over 1 billion
overweight people (WHO 2003), defined as having body mass
index (BMI) ≥25 kg/m2, of whom at least 300 million are
clinically obese (BMI ≥30 kg/m2). In the USA, an estimated 
97 million people, 65% of adults and 16% of children, are
overweight or obese (Hedley et al. 2004). These figures are
rising alarmingly: in the period from 1999 to 2002, the age-
adjusted prevalence of obesity was 31%, an increase of nearly
8% from 1988 to 1994 (Flegal et al. 2002). In the 1994–2002
Health Survey for England, obesity was present in 20% and
22% of adult males and females, respectively, with overweight
present in 45% and 34%. In addition, the prevalence of obesity
in children under 11 years of age is increasing, with 9.9% of
children affected in 1995 compared with 13.7% in 2003
(Jotangia et al. 2005). 
There are clear ethnic and gender variations in susceptibility to
obesity. Worldwide prevalence varies widely from 7% in France
to 32.8% in Brazil (Saw & Rajan 1997), and well over 40% in
some Polynesian populations (IOTF 2007). In the USA, African-
Americans, Hispanics, and American Indians or Alaska natives
are more likely than whites and Asians or Pacific Islanders to
report fair or poor health status, obesity, diabetes, and no
physical activity during leisure time (Bolen et al. 2000). Obesity
is increasingly associated with poverty, even in developing
countries (James 2004). The likelihood of being obese
increases up to around 60 years of age, and is greater 
in females.
Obesity is the most important modifiable risk factor for type 2
diabetes (Hauner 2004) and is a central feature of the metabolic
syndrome (Table 2). It is estimated that 47 million Americans,
approximately 23% of the adult population, have the metabolic
syndrome (Ford et al. 2002) as defined by the 2001 National
Cholesterol Education Program Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults
(NCEP ATP III) (NCEP 2002). The metabolic syndrome,
including elevated risk factors such as obesity, dyslipidemia,
and insulin resistance, increases the risk of later cardiovascular
disease by approximately two-fold and quadruples the risk of
developing type 2 diabetes (Meigs 2002). Type 2 diabetes is
believed to affect 18 million Americans, of whom around 
6 million are undiagnosed (CDC 2003), and is the leading cause
of adult blindness, nontraumatic amputations in adults, and
end-stage renal disease (Weinstock 2003). Metabolic syndrome
greatly increases an individual’s risk of atherosclerotic disease,
and is a predictor of cardiovascular risk independent of
baseline cardiovascular disease or diabetes (Lakka et al. 2002).
Obesity and overweight reduce overall life expectancy
(Fontaine et al. 2003) and increase the risk of developing
coronary heart disease, stroke, peripheral arterial disease, type
2 diabetes, gallbladder disease, osteoarthritis, and cancers of
the breast, prostate, colon, and endometrium. It is estimated
that life expectancy in the USA will fall in the twenty-first
century, the first decline for 200 years, if the current rate of
deaths attributable to obesity continues (Olshansky et al. 2005).
Respiratory problems, skin disorders, sleep disturbance, and
psychosocial issues including stigmatization and discrimination
may further impair quality of life in obese people.
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Category Number of records
Full papers Abstractsa
Initial search 38 121
records excluded 36 115
records included 2 6
Additional studies identified 0 0
Search update, new records 5 1
records excluded 1 0
records included 4 1
Level 1 clinical evidence
(systematic review, meta analysis)
11
Level 2 clinical evidence (RCT) 4 6b
Level ≥3 clinical evidence 1 0
trials other than RCT 0 0
case reports 1 0
Economic evidence 0 0
For definition of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website.
aIncludes abstracts presented at scientific meetings, meeting reports, opinions/highlights
articles, and other nonpeer-reviewed literature. Where a publication in this category is
included as evidence, it is deemed to be level 2 clinical evidence. 
bDuplication of published data was noted among publications identified by the initial
search. The stated value refers to the number of publications after removal of duplicated or
recycled data.
RCT, randomized controlled trial. 
Table 1 | Evidence base included in the review 
Risk factor Defining level
Abdominal obesity, waist circumference
men >102 cm (>40 in)
women >88 cm (>35 in)
Triglycerides ≥150 mg/dL (≥1.6 mmol/L)
High-density lipoprotein cholesterol
men <40 mg/dL (<1 mmol/L)
women <50 mg/dL (<1.3 mmol/L)
Blood pressure ≥130/≥85 mmHg
Fasting glucose ≥110 mg/dL (≥6.1 mmol/L)
Three or more of the above risk determinants are required to make the diagnosis of
metabolic syndrome.
Table 2 | Clinical identification of the metabolic syndrome
(NCEP 2002)Etiology
Obesity, the metabolic syndrome, and type 2 diabetes are a
closely related and convergent continuum of disease processes.
The primary cause is chronic overconsumption of energy-dense
foods coupled with physical inactivity. However, the transition
from normal weight to overweight to obesity is progressive,
complex, and multifactorial, probably beginning in early fetal
development, and governed by myriad interactions between
genotype and environment. In individuals who are genetically
predisposed to weight gain, chronic imbalance between energy
intake and expenditure leads to dysregulation of the homeostatic
mechanisms governing metabolism, energy expenditure, and
food intake. A range of physiologic and biochemical changes
ensues, including adipogenesis (weight gain), insulin resistance,
hypertension, decreased adiponectin and high-density lipoprotein
cholesterol (HDL-C), and elevated serum glucose, triglycerides
(TG), low-density lipoprotein cholesterol (LDL-C), and
proinflammatory markers (Meigs et al. 1997; Cottam et al. 2004).
Energy homeostasis: insulin, leptin, and the
endocannabinoid system
A perplexing array of neuroendocrine signaling pathways and
feedback loops involving both the central nervous system and
peripheral tissues regulate the body’s intake, metabolism,
storage, and expenditure of energy. For example, in response to
leptin and insulin secreted in the periphery, the hypothalamus
regulates caloric intake and energy expenditure by activating
anorexigenic and adipostatic pathways, reducing food intake, and
increasing metabolic rate (De Souza et al. 2005).
Insulin is normally produced and released by pancreatic beta cells
in response to hyperglycemia, and functions primarily to facilitate
the transport of glucose to the tissues (mainly liver and skeletal
muscle cells) from the bloodstream following absorption from
food in the intestines. One effect of chronic excessive food intake,
coupled with low energy expenditure, is hyperinsulinemia or
insulin resistance. This can be viewed as a compensatory
upregulation of circulating insulin in response to continued
elevated blood glucose and diminished insulin sensitivity, and is a
status strongly associated with overweight and obesity.
Hyperglycemia follows when hyperinsulinemia cannot be
maintained due to a failure of insulin production (Reaven 2005). 
Insulin also regulates leptin production by adipocytes (Havel
2000). Leptin is a pleiotropic adipocytokine that regulates appetite
and increases metabolic rate, activates sympathetic afferents,
and increases blood pressure (Rahmouni et al. 2005). Specific
genetic variations in the receptors for leptin have recently been
associated with the onset of obesity and type 2 diabetes
(Salopuro et al. 2005). Leptin levels in the circulation directly
reflect the amount of fat stored in the body, with elevated levels
found in obese patients (Considine 2005). 
The endocannabinoid system forms part of an orexigenic (food-
seeking) pathway involved with the regulation of leptin signaling
and energy homeostasis; activation of hypothalamic CB1
receptors by anandamide, sn-2 arachidonylglycerol (2-AG), or
cannabis, activates orexigenic behavior (Cota et al. 2003; Pagotto
et al. 2005). Under normal conditions, when leptin levels rise,
production of central anorexigenic neuropeptides is upregulated,
endocannabinoid activity decreases, and the resulting decrease
in CB1 receptor activation reduces appetite and food-seeking
behavior (Di Marzo et al. 2001). CB1 receptors located in gut and
adipose tissues are also involved in leptin signaling and lipid
metabolism. In obese people, a syndrome of “leptin resistance,”
similar to insulin resistance, has been described to explain the
increased circulating levels and decreased responsiveness to
leptin (Jequier 2002). An associated reduction in circulating levels
of adiponectin, an antiinflammatory adipocytokine, which can be
markedly increased by weight loss, has also been identified (Kopp
et al. 2005). This relationship suggests that pharmacologic agents
directed at the blockade of CB1 receptors may hold promise for
the treatment of obesity (Cota et al. 2003; Jbilo et al. 2005;
Pagotto et al. 2005).
The metabolic syndrome and type 2 diabetes
Central (abdominal) obesity is a key feature of the metabolic
syndrome; others include insulin resistance, atherogenic
dislipidemia, hypertension, a proinflammatory and prothrombotic
hemodynamic environment, and vascular endothelial dysfunction
(Table 2). In common with obesity, there is a genetic component to
the pathogenesis of the metabolic syndrome. However, modifiable
environmental factors such as sedentary lifestyle,
overconsumption of saturated fats, smoking, and excessive
alcohol consumption are implicated in the progression and
clustering of risk factors that characterize the metabolic syndrome.
Around 80% of obese people are insulin resistant, and insulin
resistance precedes type 2 diabetes. Defined as functional insulin
deficiency, glucose intolerance, and elevated levels of
glycosylated hemogobin (HbA1c) and fasting plasma glucose, type
2 diabetes occurs when the body can no longer supply sufficient
insulin to service the needs of its insulin-resistant tissues, because
of progressive beta-cell dysfunction and increasing magnitude of
insulin resistance (Gerich 2003). The chronic failure to maintain
glycemic control arising from type 2 diabetes causes oxidative
stress and activates pathogenic cascades in multiple tissues
including the vasculature, kidneys, and central and peripheral
nervous systems (Sheetz & King 2002; Yamagishi & Imaizumi
2005), resulting in diabetic complications such as neuropathies
and end-stage renal disease, and aggravating existing
cardiovascular disease.
Debate continues over the key etiologic process driving this
pathology (Zimmet et al. 1999; Nesto 2004; Trayhurn 2005; Ziegler
2005). It is uncertain whether the early trigger is insulin resistance
or a chronic inflammatory response to increased circulating leptin
and reduced adiponectin. However, it is clear that obesity,
metabolic syndrome, and type 2 diabetes are progressive,
convergent effects of a chronic energy imbalance. Recognition is
increasing that interventions to treat and prevent future
cardiovascular disease should address this “common 
soil” etiology.
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Burden of disease
The burden of obesity and diabetes in terms of economic and
quality of life outcomes is substantial. An estimated 5.7% of total
US healthcare expenditure is attributable to patients with BMI 
>30 kg/m2 (Wolf & Colditz 1998). In 1998, the estimated direct
healthcare expenditure on obesity in the USA (including
preventive, therapeutic, and diagnostic costs) was 
$US78.5 billion (CDC 2005). In 2002, an estimated €328 billion
was spent by the member states of the European Union on direct
and indirect costs attributed to obesity (Fry & Finley 2005). Other
factors that contribute to the social and economic burden of
obesity as annual event rates in the USA include: 40 million
workdays of productivity lost, 63 million doctors' office visits
made, 239 million restricted activity days, and 90 million bed-
bound days (Wellman & Friedberg 2002). Health-related quality of
life is negatively correlated with BMI (Larsson et al. 2002); people
who are overweight or obese may encounter psychosocial
difficulties including discrimination and stigmatization, and suffer
from psychologic distress such as depression and low self-
esteem. In 2002, the total cost in the USA of diabetes, a condition
closely linked with obesity and with high treatment costs, was
estimated at $US132 billion, of which $US90 billion were direct
healthcare costs (CDC 2003). However, this estimate is
considered to be conservative (Hogan et al. 2003). 
Current therapy options
First-line intervention for weight loss and obesity management
should involve diet modification and increased physical activity in
the context of continued nurse or physician counseling and
support. However, where these measures fail to produce
satisfactory weight loss (an appropriate treatment goal is 10%
loss of initial weight in 6 months), drug therapy may be warranted.
The US National Institutes of Health has issued guidelines for the
treatment of obesity, which recommend that all obese adults (BMI
>30 kg/m2) and all adults with a BMI >27 kg/m2 with concomitant
risk factors should be considered for drug therapy with an agent
licensed for weight loss (NIH 1998). Morbidly obese adults (BMI
>40 kg/m2) and all adults with a BMI of ≥35 kg/m2 and
concomitant risk factors are candidates for bariatric surgery.
Guidelines from the National Institute for Health and Clinical
Excellence (NICE) in England and Wales are identical except that
orlistat is indicated in patients with a BMI ≥28 kg/m2 plus
additional risk factors (NICE 2006). 
To date, no long-term prospective studies have demonstrated
that weight reduction in obese patients reduces mortality (Cerulli
& Malone 1998); yet, as mentioned above, obesity and overweight
reduce overall life expectancy. However, effective weight
management (reduction of 5–10% of initial body weight), provided
it can be maintained, can lead to clinically meaningful benefits,
and reduce the presence and future risk of obesity-related
complications. Effective weight management can improve
glycemic control, hypertension, and lipid profiles in addition to
other benefits (Valsamakis et al. 2002). Treatment modalities
include diet and behavior modification, exercise, and, where
indicated, pharmacologic intervention. Orlistat and sibutramine
are currently approved in Europe and the USA for the treatment of
obesity (Table 3), but both seem modestly effective in the long
term. Moreover, several product withdrawals and licensing
restrictions in recent years have reduced the therapeutic options
available for weight loss. Drugs licensed for other indications,
which may also promote weight loss, include bupropion,
exenatide, fluoxetine, metformin, topiramate, and zonisamide
(Kaplan 2005; Snow et al. 2005); used according to their
respective licensed labeling, such products may facilitate weight
loss as a secondary effect, but cannot be recommended as
specific interventions for obesity management. 
Orlistat
Orlistat promotes weight loss by inhibiting the absorption of
dietary fat. A potent gastrointestinal lipase inhibitor, orlistat
reduces dietary fat absorption from the digestive tract by up to
30%, reducing caloric intake by up to 200 kcal/day (Harp 1999).
The main adverse effects of orlistat are gastrointestinal
disturbances related to increased levels of fat in the stools. 
The efficacy and safety of orlistat over 4 years of treatment were
demonstrated in a placebo-controlled, randomized trial—the
longest yet reported for a weight loss intervention (Torgerson et al.
2004). Orlistat also appears to offer metabolic benefits beyond
weight loss alone, improving serum lipid, glucose, and insulin
parameters (Davidson et al. 1999; Muls et al. 2001; Hanefeld &
Sachse 2002). Orlistat therapy may cause a deficiency in fat-
soluble vitamins that may be overcome by dietary
supplementation. Gastrointestinal adverse effects, which include
oily spotting, flatus with discharge, oily evacuation, fecal
Drug class Potential adverse
effects
Advantages Disadvantages
Gastrointestinal lipase inhibitor
Orlistat Gastrointestinal
side effects 
Minimal
bioabsorption; no
central nervous
system effects.
Possible metabolic
benefits beyond
weight loss
Limited tolerability;
fat-soluble vitamin
supplements may
be required
Norepinephrine/serotonin reuptake inhibitor
Sibutramine Hypertension,
tachycardia,
palpitations
Possible metabolic
benefits beyond
weight loss
Requires blood
pressure
monitoring; should
not be prescribed
in patients with
uncontrolled or
poorly controlled
hypertension
Sympathomimetic
Phentermine Hypertension,
tachycardia,
palpitations, dry
mouth, constipation,
dizziness
Effective in short-
term weight loss
Only indicated for
short-term use;
tolerance may
develop
Table 3 | Pharmacologic agents used in the treatment 
of obesityincontinence, and increased defecation, affect up to 25% of
patients in the first year of treatment, and may limit the
therapeutic utility of orlistat. 
Sibutramine
Sibutramine is a centrally active appetite suppressant
(anorexigenic). A norepinephrine and serotonin reuptake inhibitor,
sibutramine increases satiety and reduces appetite, and may
increase energy expenditure by thermogenesis (Luque & Rey
2002). Sibutramine is associated with elevations in blood pressure
in some patients, which necessitates clinical monitoring, and
treatment must be discontinued if sustained elevations are noted.
A Health Technology Assessment by NICE concluded that the
statistically significant changes in weight relative to placebo
demonstrated in trials of sibutramine might not always translate
into clinically meaningful benefits (NICE 2001). Nonetheless,
sibutramine is also associated with improvements in various
metabolic parameters including insulin resistance, glucose, and
lipid profiles in obese people with and without type 2 diabetes
(Tankova et al. 2004), and in obese individuals with controlled
hypertension (McMahon et al. 2000). Adverse effects associated
with sibutramine include hypertension and tachycardia;
sibutramine is therefore contraindicated in patients with
uncontrolled or poorly controlled hypertension. It should not be
used for more than 1 year.
Unmet needs
Overweight and obesity are chronic conditions that require long-
term treatment; however, physicians are reluctant to treat obesity
despite the rapid increase in its prevalence (Kopelman 1999).
This may be due in part to the modest effectiveness and safety
and tolerability issues associated with current therapeutic
options, and the lack of evidence for their impact on long-term
morbidity and mortality outcomes. In addition, the number of
therapeutic options for obesity has decreased in recent years,
largely due to safety concerns. Fenfluramine and
dexfenfluramine were withdrawn worldwide in 1997 after being
linked to primary pulmonary hypertension and heart valve
abnormalities. Phenylpropanolamine, an agent with weight-
reducing effects used as an ingredient in many over-the-counter
medications, was withdrawn from the USA in 2000 because of
concerns it may cause hemorrhagic stroke. Phentermine and
amfepramone were withdrawn from Europe in 2001 because
risks were deemed to outweigh benefits, and phentermine is
licensed in the USA only for short-term weight loss. There is
therefore a clear need for safer and more effective treatment
options. The ideal profile of a new weight-reduction therapy
should deliver clinically relevant weight reduction and long-term
weight maintenance without adverse effects or the necessity for
clinical monitoring. 
Given the growing prevalence of obesity, the long-term nature of
treatment, and the difficulties many patients experience in
maintaining weight loss, there is a need to identify individuals
likely to benefit most from pharmacologic intervention.
Significant improvement in metabolic abnormalities following
weight loss is seen only in insulin-resistant obesity (Reaven et al.
2004); such patients, who represent around 80% of the obese
population, may be the most appropriate group at which to target
more intensive weight-management efforts.
A further unmet need relates to the ways outcomes in obesity
management are measured and reported. There is limited scope
for monitoring patient compliance with dietary interventions or
recommendations. In particular, clinicians have no means of
verifying patients’ actual daily caloric intake. Validated
instruments to monitor variability in compliance should therefore
be a priority in the clinical development of new weight 
loss products. 
Clinical evidence with rimonabant
Rimonabant is a novel compound which has been shown to
block endocannabinoid CB1 receptors, reduce food intake, and
promote weight loss in animal and human studies (Kirkham &
Williams 2001; Williams & Kirkham 2002; Fernandez & Allison
2004; Jbilo et al. 2005; Poirier et al. 2005). In phase II studies of
up to 16 weeks’ duration, rimonabant showed a dose-
dependent effect on weight reduction and, compared 
with placebo, was associated with significant reductions in
hunger and weekly carbohydrate consumption (Fernandez & 
Allison 2004). 
A phase III clinical development program of rimonabant in
obesity (RIO), has evaluated the effects of rimonabant on weight
loss, weight maintenance, and metabolic variables in four
placebo-controlled, randomized trials involving approximately
6600 patients (Table 4). Outcomes measured in these trials include
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Study Duration Main outcome(s) Patient 
population (n)
RIO-Europe 2 years Weight reduction
Lipid profiles
Glycemic control
Metabolic syndrome status
Obese or overweight
with or without
comorbidities,
except diabetes
(1507)
RIO-
Diabetes
1 year Weight reduction
HbA1c
Metabolic syndrome status
Obese or overweight
with type 2 diabetes
(1047)
RIO-Lipids 1 year Weight reduction
Lipid profiles
C-reactive protein
Metabolic syndrome status
Obese or overweight
with untreated
dyslipidemia,
diabetes excluded
(1033)
RIO-North
America
1 +
1 yeara
Weight reduction
Weight maintenance
Lipid profiles
Glycemic control
Metabolic syndrome status
Obese or overweight
with or without
comorbidities,
except diabetes
(3040)
aPatients rerandomized after 1 year.
HbA1c, glycosylated hemoglobin.
Table 4 | Summary of the rimonabant in obesity (RIO) clinical
development program179
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absolute and percentage weight loss; change in waist
circumference; changes in serum cholesterol levels, glycemic
parameters, blood pressure, and metabolic syndrome status;
quality of life; and safety and tolerability. 
All four RIO trials followed a similar design. After screening, a
hypocaloric diet (reduced by 600 kcal/day) was prescribed in
conjunction with a 4-week placebo run-in. Patients were then
randomized 2:2:1 to rimonabant 5 or 20 mg/day or placebo. In the
RIO-North America trial, patients were rerandomized after 
1 year to evaluate the effect of rimonabant on weight maintenance
for up to 2 years. 
Data from all four RIO trials have been published in full (Deprés et
al. 2005; Van Gaal et al. 2005; Pi-Sunyer et al. 2006; Scheen et al.
2006). Other RIO data have been presented at symposia or as late-
breaking abstracts at various scientific meetings (Anon. 2004a–c,
2005; Cleland et al. 2004; Mator 2004; NHSC 2004; Susman 2004;
Després et al. 2005b; Faxon et al. 2005; Gomaraschi 2005;
Rosenstock 2005; Shah et al. 2005). The Cochrane Collaboration
review of rimonabant included published data from RIO-Lipids,
RIO-Europe, and RIO-North America, and unpublished data from
RIO-Diabetes (Curioni & André 2006). The review provided level 1
evidence on changes in bodyweight, waist circumference, TG,
HDL-C, blood pressure, and incidence of adverse effects.
Weight reduction
There is clear level 1 evidence from the Cochrane meta analysis
that rimonabant 20 mg/day causes a significant mean reduction in
bodyweight of 4.6 kg compared with placebo after 1 year’s
treatment (Curioni & André 2006). The corresponding value for
rimonabant 5 mg/day was 1.3 kg; the pooled effect of the 
20 mg dose was 3.3 kg. The value used for bodyweight reduction
with rimonabant 20 mg from RIO-Lipids in the meta analysis was
a last observation carried forward of 6.9 kg; this study also
reported a mean reduction of 8.6 kg using a post-hoc, repeated-
measures approach, which the authors considered to be more
representative of the effects of the drug (Després et al. 2005a)
(Table 5). Van Gaal et al. (2005) reported an identical mean weight
loss in the 363 patients who completed 12 months of treatment
with rimonabant 20 mg/day. Weight loss with rimonabant 20 mg
occurred in the first 9 months of treatment and then stabilized up
to 12 months (Després et al. 2005a). In 256 patients receiving
rimonabant 20 mg/day for 2 years, mean weight loss was
maintained at 7.4 kg (Pi-Sunyer et al. 2006).
The proportions of patients achieving 5% and 10% loss of initial
body weight, generally considered to be the range of a clinically
meaningful treatment target, followed similar trends to weight loss
(Table 5). Between 21.7% and 33.2% of patients on rimonabant 
5 mg/day and 49.4% to 58.4% on 20 mg/day achieved 5% weight
loss, but for 10% weight loss, only rimonabant 20 mg was
consistently statistically superior to placebo (16.4% to 32.6%
achieved target). Again, the effect was maintained for 2 years, with
40% maintaining a 5% weight reduction and 17% maintaining a
10% reduction with rimonabant 20 mg/day (Pi-Sunyer et al. 2006). 
The Cochrane meta analysis indicates that waist circumference,
which is thought to provide a more accurate anthropometric
measure of future cardiovascular risk than BMI (Zhu et al. 2002),
was significantly reduced in patients randomized to rimonabant 5
or 20 mg compared with placebo (mean change in waist
circumference 1.2 and 3.8 cm, respectively; P<0.00001) (Curioni &
André 2006). The maximum waist circumference reduction was
achieved after 9 months of treatment, after which it remained
Table 5 | Effect of rimonabant on bodyweight indices in randomized controlled trials
Study Reference Drugs and 
dosage (n)
Duration Outcome
Weight reduction
(kg)
Waist reduction
(cm)
Patients
achieving weight
loss ≥5% (%)
Patients
achieving weight
loss ≥10% (%)
RIO-Lipids Deprés et al. 
2005a
Rim 5 (340)
Rim 20 (344)
Pla (334)
1 year 4.2a
8.6a
2.3
4.9
9.1a
3.4
NR
58.4a
19.5
NR
32.6a
7.2
RIO-Europe Van Gaal et al. 
2005
Rim 5 (603)
Rim 20 (599)
Pla (305)
1 year 3.4
6.6a
1.8
3.9
6.5a
2.4
33.2a
50.9a
19.2
10.1
27.4a
7.3
SERENADE Iranmanesh et al.
(2006)
Rim 20
Pla
6 months 6.7b
2.8
6b
2
NR
NR
NR
NR
RIO-
North America
Pi-Sunyer et al. 
2006
Rim 5 (1191)
Rim 20 (1189)
Pla (590)
1 year 1.8a,c
5.9a,c
0c
0.9c
4.5a,c
0c
26.1
48.6
20
10.6
25.2a
8.5
RIO-Diabetes Scheen et al. 2006 Rim 5 (358)
Rim 20 (339)
Pla (348)
1 year 2.3
5.3b,d
1.4
2.9
5.2b,d
1.9
21.7
49.4b,d
14.5
6.2
16.4b,d
2.0
aP<0.001 vs Pla; bResults expressed as placebo-subtracted changes from baseline; cResults reported for number of patients with data at last visit; dP<0.0001 vs Pla.
NR, not reported; Pla, placebo; Rim, rimonabant.constant, mirroring the effect on bodyweight (Després et 
al. 2005a). 
The effects of rimonabant on weight and waist circumference
were independent of baseline demographics including gender.
In severely obese patients (BMI ≥40 kg/m2), weight reduction
was reported to be comparable to the overall study population
(Van Gaal et al. 2005); however, data to support this were 
not presented. 
Adherence to the dietary protocol in RIO-Europe has been
called into question. The reported magnitude of weight loss in
the placebo-treated patients is smaller than that which would be
expected to result following a diet reduced by ~600 kcal/day for
1 year (Esposito & Giugliano 2005); the implication is that some
patients may not have complied with the dietary requirements of
the study, potentially confounding the results in favor of
rimonabant. Measuring food intake and dietetic compliance in
obesity research has been identified as a problem 
(Winkler 2005). 
Lipid profiles
Pooled data from the Cochrane meta analysis indicates a
significant reduction of 19.8 mg/dL in plasma TG and an
increase of 3.5 mg/dL in HDL-C following 1 year’s treatment with
rimonabant 20 mg/day (Curioni & André 2006). The 5 mg/day
dose was also associated with a smaller, but significant,
increase of 1.3 mg/dL. Rimonabant significantly improves ratios
of LDL: HDL and total cholesterol:HDL-C because of its lack of
effect on total cholesterol or LDL-C (Table 6). HDL-C levels
continued to increase during long-term treatment with
rimonabant 20 mg/day, with a mean rise of 9.5% compared with
placebo after 2 years in 253 patients (P<0.001) (Pi-Sunyer et al.
2006). The decrease in TG was also sustained over 2 years,
falling by 7.4% compared with placebo. 
The RIO-Lipids trial was specifically designed to investigate the
effect of rimonabant on cardiovascular risk factors in overweight 
or obese patients with dyslipidemia, defined as TG 1.7 to 
7.9 mmol/L, and total:HDL-C ratio >5 for men and >4.5 for women
(Després et al. 2005a). TG, LDL:HDL ratio, and total:HDL-C ratio
decreased significantly, and HDL-C increased significantly after 
1 year’s treatment with rimonabant 20 mg/day compared with
placebo (Table 6). LDL-C levels were not significantly decreased
during treatment with rimonabant 20 mg/day, but the peak size of
LDL particles was greater and there were fewer small particles
(Després et al. 2005a). 
There was also a substantial degree of baseline dyslipidemia,
defined as HDL-C <1.03 mmol/L, LDL-C ≥3.36 mmol/L, and TG
≥1.69 mmol/L, in the RIO-Europe study population (60.8% overall)
(Van Gaal et al. 2005). To examine the possibility of a weight loss
independent effect of rimonabant on lipid variables, logistic
regression models and/or analysis of covariance (ANCOVA) were
applied, using weight loss as the covariate. These analyses
provide estimates suggesting that only 60% of the increase in
HDL-C and 45% of the reduction in TG could be explained by the
observed weight loss; the remaining between-group differences
are presumably exerted through an undefined effect of rimonabant
on lipid metabolism. 
Whether the magnitude of the effects of rimonabant on lipid
parameters is sufficient to have implications for long-term patient
outcomes remains to be seen; however, the direction of change in
these variables is associated with reduced progression of
atherogenic and proinflammatory processes. The authors of RIO-
Europe calculate that the placebo-subtracted benefit of
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Table 6 | Effect of rimonabant on lipid profiles (values are percentage change from baseline unless otherwise specified)
Study Reference Drugs and 
dosage (n)
Duration Outcome
TC TG LDL-C HDL-C LDL:HDL TC:HDL
RIO-Lipids Deprés et al. 
2005a
Rim 5 (340)
Rim 20 (344)
Pla (334)
1 year +2.3
+2.2
+1.4
0
–15.8a
–3.6
+4.8
+8.4
+6.1
+15.6
+23.4a
+12.2
–0.31
–0.41a
–0.19
–0.57
–0.84a
–0.5
RIO-Europe Van Gaal et al. 
2005
Rim 5 (603)
Rim 20 (599)
Pla (305)
1 year +0.06b
+0.05b
+0.08b
–0.02b
–0.2a,b
–0.01b
+0.13b
+0.08b
+0.17b
+0.19b
+0.26a,b
+0.15b
NR
NR
NR
–0.52b
–0.71a,b
–0.42b
SERENADE Iranmanesh et al.
(2006)
Rim 20
Pla
6 months NR
NR
–16.3
+4.4
NR
NR
+10.1
+3.2
NR
NR
NR
NR
RIO-
North America
Pi-Sunyer et al. 
2006
Rim 5 (1191)
Rim 20 (1189)
Pla (590)
1 year NR
NR
NR
–6.6c
–16.1a,c
0c
NR
NR
NR
+2.4c
+8.6a,c
0c
NR
NR
NR
–0.15a,c
–0.32a,c
0c
RIO-Diabetes Scheen et al.
2006d
Rim 5 (358)
Rim 20 (339)
Pla (348)
1 year +3.3
+3.3
+3.3
+1.3
–9.1e
+7.3
+7.5
+6.9
+7.2
+9.2
+15.4e
+7.1
NR
NR
NR
–0.23
–0.51e
–0.16
aP<0.001 vs Pla; bmmol/L ; cResults expressed as placebo-subtracted changes from baseline; dResults reported for number of patients with data at last visit; eP<0.0001 vs Pla.
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NR, not reported; Pla, placebo; Rim, rimonabant; TC, total cholesterol; TG, triglycerides.181
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rimonabant on HDL-C increase is approximately 10% (Van Gaal et
al. 2005). This is considered to be promising given that small 
HDL-C increases incrementally reduce future cardiovascular risk
(Gordon et al. 1989). The favorable changes in HDL-C and TG
appear to be approximately double what could be attributed to
weight loss (Pi-Sunyer et al. 2006), indicating a direct effect on lipid
metabolism. The weight loss-independent effect of rimonabant
has been postulated as being due to increased mRNA expression
of adiponectin by peripheral adipose tissues, leading to beneficial
improvements in fatty-acid oxidation (Van Gaal et al. 2005). 
An analysis of adiponectin levels in RIO-Lipids (Després et al.
2005a) has reported significant increases in plasma adiponectin 
of 2.7 mcg/mL following treatment for up to 1 year with 
rimonabant 20 mg (P<0.001 vs placebo). The increases positively
correlated with HDL-C, and 57% of the increase was weight 
loss independent. 
Glycemic control
Rimonabant 20 mg/day for up to 1 year showed beneficial effects
on glycemic parameters including serum levels of fasting glucose
and insulin, HbA1c, and insulin resistance in obese and overweight
patients (Table 7). These benefits appear to stem from stabilization
of the declining glycemic control normally associated with obesity.
As with lipids, the beneficial changes of rimonabant on fasting
insulin, insulin resistance, and HbA1c, are roughly twice what could
be predicted from weight loss, suggesting a direct effect on
glucose metabolism. 
A pooled subgroup analysis of 1-year data from patients in
RIO-Lipids, RIO-Europe, and RIO-North America with impaired
fasting glucose (IFG) or “prediabetes,” defined as fasting
glucose of 100–125 mg/dL (5.56–6.94 mmol/L), reported
significant differences in weight loss relative to placebo for both
5 and 10 mg rimonabant in the intention-to-treat population
(Rosenstock 2005). Significant improvements relative to
placebo were also noted in lipid profiles, fasting insulin levels,
and homeostasis model assessment–insulin resistance (HOMA-
IR) in patients treated with rimonabant 20 mg. Nonsignificant
trends favoring rimonabant were noted in the proportions of
patients with IFG, normal fasting glucose, and type 2 diabetes
after 1 year’s treatment. 
RIO-Diabetes studied the effects of rimonabant in overweight
or obese patients with type 2 diabetes receiving metformin 
or a sulfonylurea (Scheen et al. 2006). There were significant
decreases in fasting glucose, fasting insulin, HbA1c, as well 
as insulin resistance with rimonabant 20 mg/day (Table 7).
Sixty-eight percent of patients taking rimonabant 20 mg/day
achieved a target HbA1c level of <7% compared with 
48% of placebo recipients (P<0.0001), and 43% achieved 
a level <6.5% versus 21% on placebo (P<0.0001). HbA1c was
not affected by concomitant metformin or sulfonylureas.
Dosages of other antidiabetic drugs were increased in 11.3%
and 12.8% of patients taking rimonabant 20 mg/day and
placebo, respectively, and decreased in 11.9% and 7.5% 
of patients. 
Similarly, mean HbA1c was reduced by 0.8% after 6 months in
treatment-naïve patients with type 2 diabetes receiving
rimonabant 20 mg/day compared with 0.3% with placebo
(Iranmanesh et al. 2006).
The metabolic syndrome 
RIO-Europe, RIO-North America, RIO-Lipids, and RIO-Diabetes
provide good evidence that rimonabant 20 mg may significantly
reduce the incidence of the metabolic syndrome in obese patients
Table 7 | Effect of rimonabant on glycemic indices
Study Reference Drugs and 
dosage (n)
Duration Outcome
Fasting glucose
(mmol/L)
HbA1c (%) Fasting insulin
(mcU/mL)
HOMA-IR
RIO-Lipids Deprés et al. 
2005a
Rim 5 (340)
Rim 20 (344)
Pla (334)
1 year +0.01
–0.09
–0.02
NR
NR
NR
+0.6
–1.3
+0.7
NR
NR
NR
RIO-Europe Van Gaal et al. 
2005
Rim 5 (603)
Rim 20 (599)
Pla (305)
1 year –0.05
–0.09
+0.03
NR
NR
NR
+0.3
–1.0a
+1.8
0
–0.3
+0.4
SERENADE Iranmanesh et al.
(2006)
Rim 20
Pla
6 months NR
NR
–0.8b
–0.3
NR
NR
NR
NR
RIO-
North America
Pi-Sunyer et al. 
2006
Rim 5 (1191)
Rim 20 (1189)
Pla (590)
1 year –0.31 mg/dLc,d
–0.69c,d
0c,d
NR
NR
NR
–1.7d
–2.7a,d
0d
–0.6d
–0.8d
0d
RIO-Diabetes Scheen et al. 2006e Rim 5 (358)
Rim 20 (339)
Pla (348)
1 year +0.3
–0.64f
+0.33
–0.1
–0.6f
+0.1
+0.7
–0.7
+0.4
+0.6
–0.5
+0.6
aP<0.001 vs Pl; bP=0.0002 vs Pla; cmg/dL; dResults expressed as placebo-subtracted changes from baseline; eResults reported for number of patients with data at last visit; fP<0.0001 vs Pla.
HbA1c, glycosylated hemoglobin; HOMA-IR, homoeostasis model assessment of insulin resistance; NR, not reported; Pla, placebo; Rim, rimonabant.(Table 8). This is encouraging given the high prevalence of the
metabolic syndrome in this population, and suggests that
rimonabant could potentially reduce the burden of risk factor
management in obesity. 
The prevalence of the metabolic syndrome [defined by NCEP ATP
III criteria (Table 2)] decreased in all patients after 1 year’s
treatment. However, the reduction was significant with
rimonabant 20 mg/day versus placebo. The difference between
rimonabant 5 mg and placebo did not reach statistical
significance for this outcome.
These findings suggest that rimonabant 20 mg may produce
clinically meaningful reductions in obese patients presenting with
the metabolic syndrome, with consequent implications for risk
factor management and improvements in prognosis. The
reduction in the metabolic syndrome appears to be a result of the
decrease in waist circumference and increase in HDL-C (Després
et al. 2005a). Detailed analyses of these independent effects
would be of value in clinical decision making, and would help to
improve understanding and identification of those patients most
likely to benefit from rimonabant. 
Blood pressure and heart rate 
There is level 1 evidence based on the results of RIO-Europe,
RIO-Lipids, and RIO-Diabetes, that rimonabant 20 mg/day results
in a mean reduction in systolic blood pressure of 2 mmHg and
diastolic blood pressure of 1 mmHg (Curioni & André 2006). The
5 mg/day dose has no statistically significant effect, and the meta
analysis indicated that because of substantial heterogeneity in the
results, the pooled data on blood pressure were unreliable.
Results from RIO-North America support these findings (Table 9). 
The lack of a significant effect of rimonabant on blood pressure
supports the use of rimonabant in obese patients with
concomitant hypertension. This is potentially an important
advantage given that obesity and hypertension often present
together. Indeed, there is evidence that decreases in blood
pressure are greater in patients with hypertension (baseline blood
pressure ≥140/90 mmHg), with a mean reduction of 13.1/6.3 with
rimonabant 20 mg/day compared with 7.2/2.4 mmHg with
placebo (Després et al. 2005a).
However, concern has been raised that the weight loss
associated with rimonabant in RIO-Europe did not produce
significant reductions in blood pressure (Astrup 2005). Weight
loss of the reported magnitude with rimonabant 20 mg might be
expected to reduce blood pressure by ~4 mmHg. 
Heart rate appears to be unaffected by rimonabant (Després et al.
2005a; Van Gaal et al. 2005). 
Quality of life 
There is evidence from one RCT that rimonabant 20 mg/day
improves quality of life. The RIO-Diabetes study evaluated
patients’ quality of life using the Short-Form 36 questionnaire
(SF-36) and the obesity-specific Impact of Weight on Quality of
Life (IWQoL-Lite) instruments, and food behavior using a visual
analog scale.
The study reported that more patients taking rimonabant 
20 mg/day reported satisfaction compared with placebo
(P=0.001), and showed a greater improvement in physical
function, self-esteem, and total IWQoL-Lite score (Scheen et al.
2006). There was less desire for high-fat foods and sweets,
greater ease of following diet, and reduced appetite in patients
taking rimonabant. However, impairment in mental health score
was greater in rimonabant recipients.
Safety and tolerability
Based on the pooled results from RIO-Europe, RIO-North
America, and RIO-Diabetes, the Cochrane meta analysis revealed
that there were significantly more general adverse events 
(1852 events in 2157 patients vs 1031/1260; P=0.005) and serious
adverse events (149/2503 vs 69/1602; P=0.03) in patients
receiving rimonabant 20 mg/day compared with placebo (Curioni
& André 2006). Discontinuation of treatment due to tolerability
was also significantly more common in patients receiving
rimonabant 20 mg/day (13.8% vs 7%; P<0.00001). The
tolerability profile of the 5 mg/day dose did not differ 
from placebo. 
The most common adverse events reported by ≥5% of patients
taking rimonabant 20 mg/day included nausea, dizziness,
diarrhea, anxiety, upper respiratory tract infection/influenza,
insomnia, and arthralgia (Després et al. 2005a; Van Gaal et al.
Rimonabant | place in therapy review
© 2007 Core Medical Publishing Limited 182
Table 8 | Effect of rimonabant on prevalence of the metabolic
syndromea
Study Reference Drugs and 
dosage (n)
Duration Decrease in
prevalence of
metabolic
syndrome (%)
RIO-Lipids Deprés et 
al. 2005
Rim 5 (340)
Rim 20 (344)
Pla (334)
1 year 28.4
51.2b
21
RIO-
Europe
Van Gaal et
al. 2005
Rim 5 (603)
Rim 20 (599)
Pla (305)
1 year 30.6
53.6b
21.3
RIO-North
America
Pi-Sunyer et
al. 2006
Rim 5 (1191)
Rim 20 (1189)
Pla (590)
1 year NR
39b
7.9
RIO-
Diabetes
Scheen et 
al. 2006c
Rim 5 (358)
Rim 20 (339)
Pla (348)
1 year 22d
26d
18d
aMetabolic syndrome defined according to criteria of the National Cholesterol 
Education Program Adult Treatment Panel III (see Table 2); bP<0.001 vs Pla; 
cResults reported for number of patients with data at last visit; dReported as percentage
achieving “improvement.”
NR, not reported; Pla, placebo; Rim, rimonabant.183
2005; Pi-Sunyer et al. 2006; Scheen et al. 2006). These events
were generally considered to be mild to moderate in intensity and
transient in nature, occurring mainly during the first months of the
study. However, the high drop-out rate must also be considered.
The available data suggest that rimonabant has a different
tolerability profile to existing weight reduction therapies; in
particular it does not appear to be associated with severe
gastrointestinal adverse effects, clinically relevant elevations in
blood pressure, or changes in liver, kidney, or blood physiology. 
Since rimonabant is a centrally active novel pharmacologic agent,
neuropsychologic effects must be considered a theoretical
adverse effect warranting investigation. Indeed, the main category
of adverse event leading to discontinuation of rimonabant 
20 mg/day was depressed mood. Patients with serious
psychologic illness, neuropsychiatric disorders, or severe
depression involving hospitalization, recurrent episodes, or suicide
attempts, were excluded from RIO-Europe, RIO-North America,
and RIO-Lipids (Després et al. 2005a; Van Gaal et al. 2005; 
Pi-Sunyer et al. 2006). To evaluate possible effects of rimonabant
on mood and mental state, the Hospital Anxiety and Depression
(HAD) rating scale, a short patient-reported questionnaire
designed to screen for mood and psychiatric disorders in the
primary care setting, was completed at baseline and at 3-month
intervals in RIO-Europe, RIO-North America, and RIO-Diabetes.
Patients scoring ≥11 on HAD were referred to a psychiatrist for
further assessment and treatment if necessary. After 1 year, there
were no significant between-group differences in the mean
(standard deviation) HAD scale subscores for depression (Després
et al. 2005a; Van Gaal et al. 2005; Scheen et al. 2006).
Pharmacoepidemiologic evidence from the approximately 
240000 patients who have received rimonabant worldwide
indicates that one in ten may develop psychiatric side effects
(MHRA 2007). In the UK, 318 cases of adverse events (921 events
in total because of multiple events in the same patients) associated
with rimonabant had been reported up to June 2007 in an
estimated 41000 patients receiving the drug, including 
364 neuropsychologic effects, of which 48 were depression, 16
were suicidal thoughts, and 1 was self harm (MHRA 2007). 
Multiple sclerosis has been reported in one female patient who
participated in RIO-Europe and had been taking rimonabant 
5 mg/day for approximately 6 months (van Oosten et al. 2004).
This patient had no previous signs of neurologic illness. Her
symptoms improved somewhat before discontinuation of
rimonabant, but in the weeks after stopping the medication she
made an almost complete recovery. The efficacy of cannabinoid
agonists in slowing the degenerative pathology of multiple
sclerosis has been documented, and provides a theoretical basis
for cannabinoid blockade by rimonabant exacerbating the same
pathologic processes. However, it is not possible to determine
whether multiple sclerosis developed in this patient as a direct
consequence of exposure to rimonabant. 
Resource utilization
Rimonabant could have a significant impact on healthcare
resource utilization, not only because of the large numbers of
patients who may be eligible for treatment, but also because the
available evidence suggests that rimonabant might reduce the
need for polypharmacy in cardiovascular risk factor management.
Pharmacoeconomic and resource utilization data relating to
rimonabant have yet to be published. However, the encouraging
efficacy and safety data published to date suggest that
rimonabant could have a substantial impact on clinical practice in
the management of patients with the metabolic syndrome and
multiple cardiovascular risk factors. The additional metabolic
benefits rimonabant seems to offer beyond weight loss, such as
improved lipid and glycemic profiles, could potentially reduce the
need for polypharmacy in risk factor modification, leading to
reductions in overall obesity-related healthcare resource utilization.
The cost of 1 year’s treatment with rimonabant 20 mg/day was
reported as £719 in October 2006 in the UK (MTRAC 2006).
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Table 9 | Effect of rimonabant on blood pressure (mmHg) and heart rate (bpm)
Study Reference Drugs and 
dosage (n)
Duration Outcome
DBP SBP HR
RIO-Lipids Deprés et al. 2005 Rim 5 (340)
Rim 20 (344)
Pla (334)
1 year –0.5
–2.9a
–0.8
–0.4
–3.6
–0.7
+0.2
+0.9
+0.7
RIO-Europe Van Gaal et al. 2005 Rim 5 (603)
Rim 20 (599)
Pla (305)
1 year –1.5
–1.8
–0.4
–1.3
–2.0
–0.4
NR
NR
NR
RIO-North America Pi-Sunyer et al. 2006 Rim 5 (1191)
Rim 20 (1189)
Pla (590)
1 year +0.2b
–0.2b
0a
+0.2b
–0.3b
0a
NR
NR
NR
RIO-Diabetes Scheen et al. 2006c Rim 5 (358)
Rim 20 (339)
Pla (348)
1 year –0.4
–1.9
–0.7
–0.4
–0.8
+1.6
+0.9
+1.0
+0.8
aP=0.002 vs Pla; bResults expressed as placebo-subtracted changes from baseline; cResults reported for number of patients with data at last visit.
DBP, diastolic blood pressure; HR, heart rate; NR, not reported; Pla, placebo; Rim, rimonabant; SBP, systolic blood pressure.Patient group/population
Rimonabant is approved in the European Union as an adjunct to
diet and exercise for the treatment of obese (BMI 
≥30 kg/m2) or overweight patients (BMI >27 kg/m2) with
associated risk factors including type 2 diabetes or dyslipidemia.
It is not available in the USA.
Obesity is an umbrella term which tends to be applied to a highly
heterogeneous and diverse cross-section of people of different
ages, ethnic groups, socioeconomic status, and medical
histories. RIO-Europe was designed to be representative of a real-
world clinical setting (Van Gaal et al. 2005), but the authors of
RIO-North America, which included patients with very similar
characteristics, acknowledge their study had limited
generalizability to clinical practice due to the overrepresentation
of white women in the study population (Pi-Sunyer et al. 2006).
Caution should therefore perhaps be exercised when
extrapolating these data to the full spectrum of cases that present
in clinical practice.
There is, nevertheless, evidence that rimonabant 20 mg/day is
effective in reducing bodyweight in obese or overweight patients
with dyslipidemia and those with type 2 diabetes. The drug also
appears to improve glucose control in diabetic patients previously
untreated (Iranmanesh et al. 2006) or who are poorly controlled on
metformin or sulfonylureas (Scheen et al. 2006). Weight loss may
be lower in black patients due to higher clearance of the drug
(Anon. 2007a). 
Dosage, administration, and formulations
The dosage of rimonabant (Acomplia) in obese or overweight
patients is 20 mg/day orally in the morning before breakfast
(Anon. 2007a). No dosage adjustment is required for elderly
patients, or those with mild to moderate hepatic or renal
impairment. Rimonabant should be used with caution in patients
with moderate hepatic impairment and is contraindicated in
severe hepatic or renal impairment. It is not recommended in
patients under the age of 18 years or during pregnancy, and
should only be used with caution in patients aged over 75 years
and those with epilepsy. The European Medicines Agency (EMEA)
recently recommended that rimonabant should not be used in
patients with major depression or taking antidepressants (EMEA
2007). Caution is also recommended if given in combination with
the potent CYP3A4 inhibitors ketoconazole, itraconazole,
ritonavir, clarithromycin, telithromycin, and nefazodone, which
may increase plasma levels of rimonabant. Conversely, CYP3A4
inducers like rifampicin, phenytoin, carbamazepine, and St John’s
Wort may decrease levels. 
Place in therapy
The available evidence on rimonabant 20 mg/day from four large-
scale RCTs indicates efficacy for up to 2 years on weight loss and
across a range of cardiovascular and metabolic risk factors in
obese and overweight patients, and in patients with diabetes and
dyslipidemia (see the Evidence summary table on the opening
page of this article). Approximately 50% of patients achieve
weight loss of ≥5%, with ≥10% in 16–32% of patients. These
values are important because the Food and Drug Administration
(FDA) threshold for antiobesity drugs is placebo-subtracted
weight loss of ≥5%, while that for the EMEA is ≥10%, with both
requiring a significant difference compared with placebo (Curioni
& André 2006). However, the FDA recently recommended that
rimonabant should not be approved for use in obese and
overweight patients with additional risk factors due to the risk of
adverse psychiatric effects (Anon. 2007b); the EMEA concluded
that the benefits of the drug outweigh the risks except in patients
with major depression or taking antidepressants (EMEA 2007).
There are some concerns regarding the strength of the evidence
for rimonabant’s efficacy. First, the drop-out rate across all groups
in the studies was high—approximately 40%. Adverse events
caused around 14% of rimonabant recipients to discontinue the
drug (see above), while almost three times as many patients who
gained weight stopped treatment (Scheen et al. 2006). Second,
the studies have been criticized for inconsistently reporting
methods of randomization, blinding, and statistical power
calculations (Curioni & André 2006). Third, the results may not be
generalizable to clinical practice because of the highly selected
patient populations (e.g. overrepresentation of white women) 
(Pi-Sunyer et al. 2006). 
The trials were also all comparisons with placebo, rather than
active drugs. The meta analysis of the RIO trials indicated a mean
weight reduction of 4.6 kg with rimonabant 20 mg/day after 1 year
compared with placebo (Curioni & André 2006). This is greater
than the decreases of 2.7 kg with orlistat and 4.3 kg with
sibutramine reported in another meta analysis (Padwal et al.
2003), although any differences would need to be substantiated in
head-to-head comparisons. Furthermore, orlistat is associated
with gastrointestinal adverse effects and lower HDL-C levels, and
sibutramine with increased blood pressure. Another meta analysis
in patients with diabetes reported mean weight loss of 2.6 kg with
orlistat and 4.5 kg with sibutramine (Norris et al. 2004); in RIO-
Diabetes, rimonabant 20 mg/day reduced weight by 5.3 kg
(Scheen et al. 2006). HbA1c decreased by 0.6%, compared with
corresponding values of 0.4% with orlistat and 0.7% with
sibutramine in the meta analysis (Norris et al. 2004).
There is preliminary evidence that rimonabant lowers HbA1c by
0.8% in previously untreated diabetic patients, who also lost a
mean of 6.7 kg in bodyweight (Iranmanesh et al. 2006). The
evidence also points to a beneficial decrease in fasting glucose,
fasting insulin, and insulin resistance with rimonabant in obese or
overweight patients. Furthermore, other cardiovascular risk
factors improved during rimonabant treatment, including
increased HDL-C and adiponectin, and reduced TG, LDL:HDL
and total:HDL-C ratios, and leptin and C-reactive protein levels. A
direct effect of rimonabant has been suggested since changes in
HbA1c, HDL-C, TG, and adiponectin were independent of weight
loss. The mechanism may be blockade of CB1 receptors by
rimonabant leading to increased production of adiponectin, which
would result in reduced abdominal fat deposition, and hence
lower cardiovascular risk (Després et al. 2005a; Van Gaal et al.
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2005). Indeed the evidence shows that rimonabant significantly
reduces waist circumference, and the prevalence of the 
metabolic syndrome.
The weight loss of ≥5% achieved with rimonabant 20 mg/day
together with the beneficial effects on lipid and glucose
metabolism indicate that the drug should reduce cardiovascular
risk in obese and overweight patients, including those with
diabetes. Diet and exercise remain the first-line options for
managing weight loss but in those patients who require an
additional pharmacologic intervention, the evidence suggests that
rimonabant appears effective. The long-term effectiveness of any
intervention aimed at reducing weight is obviously dependent on
patient compliance, which is often poor. Patient support, such as
the program provided by the manufacturer of rimonabant, may
help to improve this aspect of treatment. 
Although implied by what is currently available, there is at present
no hard evidence that the beneficial effects of rimonabant on risk
factors translate into cardiovascular endpoints. The ongoing
CRESCENDO (Comprehensive Rimonabant Evaluation Study of
Cardiovascular Endpoints and Outcomes) trial will be particularly
important in this regard. The primary objective of this double-blind
RCT, which is expected to enroll 17000 patients aged ≥55 years
with abdominal obesity and other cardiovascular risk factors, is to
show whether rimonabant 20 mg/day reduces the risk of
myocardial infarction, stroke, or death from a myocardial
infarction or stroke. The results are awaited with interest.  
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